Taking Action Against Chronic Hepatitis B Infection
This activity offers CE credit for:%>
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Monday, June 18, 2018
Note: Credit Is No Longer Available
|Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF
Director, Liver Care Network and Organ Care Research
Swedish Medical Center
|Robert S. Brown, Jr., MD, MPH
Vice Chair of Medicine
Interim Chief, Gastroenterology and Hepatology
Weill Cornell Medical College
Director of the Center for Liver Disease and Transplantation
New York Presbyterian Hospital
New York, NY
|Steven-Huy Han, MD, AGAF, FAASLD
Director, Hepatology Clinical Research Center
Professor of Medicine and Surgery
Assistant Director, UCLA Asian Liver Center
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, CA
Hepatitis B virus (HBV) infection is a largely undetected and untreated disease in the United States. Only 33% of the estimated one million Americans living with HBV are aware that they are infected, placing them at risk for spreading the infection to others, and developing liver failure, cirrhosis, or hepatocellular carcinoma (HCC). As a result, HBV infection is the most common reason for liver transplantation.1
Primary care providers are not adequately screening at-risk patients for HBV infection and counseling patients related to risk. In a CME Outfitters outcomes report, 68% of physicians in the control group did not accurately identify a patient that should be assessed according to CDC guidelines.2 In a study of general practitioners and patients with HBV, most general practitioners reported not using screening protocols or official guidelines to direct screening decisions. One physician stated, “[There’s a] considerably big difference in the mindset of the doctors.”2
In this CME Outfitters Live and On Demand panel discussion, national experts will provide strategic education to primary care providers who manage patients with HBV on screening for HBV, interpreting serology results, and counseling patients throughout the treatment process with the goal of optimizing long-term patient outcomes.
- U.S. Department of Health and Human Services [HHS]. Action plan for the prevention, care, & treatment of viral hepatitis 2014-2016. HHS Website. http://aids.gov/pdf/viral-hepatitis-action-plan.pdf. Published February, 2014. Accessed April 1, 2015.
- Wallace J, Hajarizadeh B, Richmond J, McNally S. Investigating general practice and hepatitis B. LaTrobe University Website. https://www.latrobe.edu.au/arcshs/downloads/arcshs-research-publications/General-Practice-and-Hepatitis-B-Final-Report.pdf. Published 2012. Accessed April 1, 2015.
At the end of this CE activity, participants should be able to:
- Increase the rate at which health care providers screen at-risk patients for HBV infection by 20%.
- Educate and counsel HBsAg-positive patients about the significance of their serologic findings and discuss next treatment steps for HBV infection.
- Devise a plan or refer patients for ongoing monitoring, follow-up, and determination of treatment candidacy for HBV infection.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Identify the rate at which health care providers screen at-risk patients for HBV infection.
- Define the significance of serologic findings and next treatments steps for HBV infection.
- Explain the plan for ongoing monitoring, follow-up, and determination of treatment candidacy for HBV infection.
Supported by an educational grant from Gilead Sciences, Inc.
Physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other health care professionals interested in HBV infection.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.
Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1.5 contact hours of pharmacotherapeutic contact hours.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.5 CEUs)
Universal Activity Number: 0376-0000-15-017-L01-P (live programs)
0376-0000-15-017-H01-P (recorded programs)
Activity Type: knowledge-based
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Kowdley has disclosed that he has received research grants from Evidera; Gilead; Immuron; Intercept Pharmaceuticals, Inc.; and Tobira Therapeutics, Inc. He serves as a consultant to/is on the advisory boards of AbbVie Inc.; Achillion Pharmaceuticals; Bristol-Myers Squibb Company; Evidera; Gilead; Merck & Co., Inc.; Novartis Corporation; Trio Health. He has received other financial or material support from UpToDate, Inc. (educational website, royalties received)
Dr. Brown has disclosed that he has received grants/research support from AbbVie Inc.; Gilead Sciences Inc.; Janssen Pharmaceuticals, Inc.; and Merck & Co., Inc. He is on the speakers bureaus of AbbVie Inc.; Gilead Sciences Inc.; Janssen Pharmaceuticals, Inc.; and Merck & Co., Inc.
Dr. Han has disclosed that he has received research grants from Bristol Myers Squibb Company; Gilead Sciences Inc.; and Idenix Pharmaceuticals/Novartis Corporation. He serves on the speakers bureau of AbbVie Inc.; Bristol Myers Squibb Company; and Gilead Sciences Inc. He serves as a consultant to AbbVie Inc.; Bristol Myers Squibb Company; and Gilead Sciences Inc.
Ruth Cody, BSN, RN-BC (content/peer reviewer) has no disclosures to report.
Frances C. Daniel, MPH (planning committee) has no disclosures to report.
Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.
Disclosures have been obtained from CME Outfitters staff: No disclosures to report.
Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
CME Outfitters, LLC, the faculty, and Gilead Sciences, Inc. do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).